Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells

• Published in: Regenerative medicine Vol. 9; no. 5; pp. 621 - 635
• Main Authors: Schnabel, Lauren V, Abratte, Christian M, Schimenti, John C, Felippe, M Julia Bevilaqua, Cassano, Jennifer M, Southard, Teresa L, Cross, Jessica A, Fortier, Lisa A
• Format: Journal Article
• Language: English
• Published: Future Medicine Ltd 01.01.2014
• Subjects: allogeneic stem cell therapy; immunogenicity; immunomodulatory; induced pluripotent stem cell; mesenchymal stromal cell; transplantation medicine
• ISSN: 1746-0751; 1746-076X
• DOI: 10.2217/rme.14.29

To evaluate the immunogenic and immunomodulatory properties of induced pluripotent stem cells (iPSCs) compared with bone marrow-derived mesenchymal stromal cells (MSCs). Mouse embryonic fibroblasts (MEFs) were isolated from C3HeB/FeJ and C57BL/6J mice, and reprogrammed to generate iPSCs. Mixed leukocyte reactions were performed using MHC-matched and -mismatched responder leukocytes and stimulator leukocytes, iPSCs or MSCs. To assess immunogenic potential, iPSCs and MSCs were used as stimulator cells for responder leukocytes. To assess immunomodulatory properties, iPSCs and MSCs were cultured in the presence of stimulator and responder leukocytes. MEFs were used as a control. iPSCs had similar immunogenic properties but more potent immunomodulatory effects than MSCs. Co-culture of MHC-mismatched leukocytes with MHC-matched iPSCs resulted in significantly less responder T-cell proliferation than observed for MHC-mismatched leukocytes alone and at more responder leukocyte concentrations than with MSCs. In addition, MHC-mismatched iPSCs significantly reduced responder T-cell proliferation when co-cultured with MHC-mismatched leukocytes, while MHC-mismatched MSCs did not. These results provide important information when considering the use of iPSCs in place of MSCs in both regenerative and transplantation medicine.